Replies to post #24111 on Cytogenix (fka CYGX)

[Paulness]

Dr. Malcolm Skolnick, CytoGenix President and CEO commented, "Once you eliminate the bacteria, the scale of production and related costs of DNA come way down. This technology transcends economic implications. More importantly, we have introduced a fundamental improvement to the science of making DNA. For example, DNA vaccines are made of DNA "rings" called plasmids. Scientists design these plasmids to contain instructions that "prompt" the immune system to identify and destroy a viral or bacterial pathogen, such as those that cause AIDS, SARS or influenza."

"Along with the therapeutic DNA, the traditional bacteria-based technology requires that the plasmid contain DNA "instructions" for its replication in E. coli as well. These extraneous bacterial genes are not entirely benign and can elicit serious side effects. By eliminating the need for this extra DNA, the plasmids are significantly smaller and safer, thus enabling greater drug concentrations if required. We believe that by eliminating these extra pieces in the DNA plasmid, scientists will now have much more freedom and control in designing better and safer DNA drugs."

"We will use this technology to reduce the costs of the DNA needed for the clinical trials of our herpes anti-viral and anti-inflammatory topical products as well as making the technology available to others through licensing or contract manufacturing," adds, Dr. Skolnick

[Tatonkano62]

Oh hogger, I'm going to make your night with this one.


CytoGenix Announces a Research Agreement with University of Texas Health Science Center Houston for Pre-Clinical Testing of a Gene Silencing Anti-Bacterial Agent Against Sepsis

Houston, TX, (December 15, 2003) Cytogenix, Inc. (OTCBB: CYGX)

CytoGenix, Inc. (OTCBB: CYGX) announced Monday that it has entered into an agreement with the University of Texas Health Science Center Houston Medical School, for animal studies using the company's proprietary ssDNA technology against a gene that when silenced, inhibits bacterial reproduction.

Dr. Jeffrey K. Actor, associate professor, department of pathology and laboratory medicine, will conduct these proof-of-concept studies to determine the effect of this technology on bacterial sepsis induced in mice.

Sepsis is a life-threatening syndrome resulting from bacterial or fungal infection of the blood that can occur after trauma or surgery. Cases of sepsis have risen dramatically in the last twenty years from 164,000 in 1979 to more than 750,000 in 2002; about 215,000 Americans die annually from severe sepsis. Traditional antibiotic therapy has become ineffective because the sepsis causing pathogens have mutated and developed defenses against all but the most powerful and expensive treatments. Care of people with sepsis costs about $50,000 per case resulting in an economic burden of nearly $17 billion a year.

"This can be a very significant development in the fight against infectious diseases." stated Dr. Actor. "Sepsis is a very complex condition that acts very quickly especially against immune-compromised or otherwise weakened individuals. Any improvement in treatment options will be a very important medical development." adds Dr. Actor.

"We have chosen sepsis as the first application of our anti-bacterial because it is a life-threatening condition and a significant economic burden to society; the results of these early trials can lead to the development of a very important therapeutic product." states, Dr. Malcolm Skolnick, CytoGenix, Chairman and CEO.

Well, this was the first anti-bacterial application. But wait...we forgot to conclude the herpes studies. I look back on this and have to laugh. Did they sit around in a room smoking cigars saying, "First we'll throw them the herpes, then sepsis. Later we will spout cancer and psoriasis. Went we've exhausted all avenues, we'll change directions. We'll say we need syn DNA and increase our shares by 18 million. These guys are laughing all the way to the bank. They don't take calls, they don't answer emails, and if you get through their answers take on a serpentine direction. Straight shooters my arse.

CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including, anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a US patent for its core DNA expression technology and has 40 international or US pending patent applications.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.

Contact: Communications Director — Juan Ferreira, [phone]

Tonights entertainment brought to you from.....

Tatonkano